City Holding CO Crispr Therapeutics Ag Transaction History

City Holding CO

$641 Million
Q1 2024

A detailed history of City Holding CO transactions in Crispr Therapeutics Ag stock. As of the latest transaction made, City Holding CO holds 85 shares of CRSP stock, worth $4,524. This represents 0.0% of its overall portfolio holdings.

Number of Shares

Previous 114 25.44%

Holding current value

$4,524

Previous $7,000 28.57%

% of portfolio

0.0%

Previous 0.0%

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 Apr 11, 2024	SELL	$60.67 - $89.12 $1,759 - $2,584	-29 Reduced 25.44%	85 $5,000
Q4 2023 Jan 10, 2024	SELL	$38.62 - $72.18 $2,317 - $4,330	-60 Reduced 34.48%	114 $7,000
Q3 2023 Oct 13, 2023	SELL	$45.39 - $59.0 $71,262 - $92,630	-1,570 Reduced 90.02%	174 $7,000
Q2 2023 Jul 13, 2023	SELL	$43.47 - $67.77 $21,735 - $33,885	-500 Reduced 22.28%	1,744 $97,000
Q1 2023 Apr 17, 2023	SELL	$41.0 - $56.12 $27,470 - $37,600	-670 Reduced 22.99%	2,244 $101,000

Q4 2022 Jan 27, 2023	SELL	$39.19 - $65.67 $18,223 - $30,536	-465 Reduced 13.76%	2,914 $0
Q3 2022 Oct 12, 2022	SELL	$61.1 - $83.78 $21,996 - $30,160	-360 Reduced 9.63%	3,379 $221,000
Q2 2022 Jul 08, 2022	SELL	$43.23 - $73.83 $152,818 - $260,989	-3,535 Reduced 48.6%	3,739 $227,000
Q1 2022 Apr 15, 2022	SELL	$53.19 - $79.24 $10,106 - $15,055	-190 Reduced 2.55%	7,274 $457,000
Q4 2021 Mar 11, 2022	BUY	$70.09 - $111.29 $26,423 - $41,956	377 Added 5.32%	7,464 $458,000
Q3 2021 Oct 15, 2021	BUY	$110.2 - $156.64 $316,604 - $450,026	2,873 Added 68.18%	7,087 $793,000
Q2 2021 Jul 15, 2021	BUY	$100.84 - $161.89 $117,680 - $188,925	1,167 Added 38.3%	4,214 $682,000
Q1 2021 Apr 15, 2021	BUY	$110.72 - $210.04 $337,363 - $639,991	3,047 New	3,047 $371,000

Others Institutions Holding CRSP

# of Institutions

550

Shares Held

56.3M

Call Options Held

2.91M

Put Options Held

2.47M

View Full List

About CRISPR Therapeutics AG

Ticker CRSP
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 78,009,296
Market Cap $4.15B
Description
CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious diseases using its proprietary Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. Its CRISPR/Cas9 is a gene editing technology that allows for precise directed changes to genomic DNA....

More about CRSP

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of City Holding CO, based on Form 13F filings with the SEC.

News

Stay updated on City Holding CO with notifications on news.

Account